Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28538491 | 0.92 | NPC1 (0.62) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL29154843 | 0.87 | RAB9A (0.56) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL9446510 | 0.82 | KAT2B (0.54) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL28721561 | 0.82 | PKM (0.62) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7170020 | 0.81 | KAT2B (0.81) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6200169 | 0.81 | KAT2B (0.81) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7745470 | 0.80 | ALDH1A1 (0.66) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6198359 | 0.79 | KAT2B (0.78) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL8720672 | 0.79 | KAT2B (0.78) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL29155075 | 0.79 | RAB9A (0.47) | KAT2BNPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | KAT2B 878/4885NPC1 3492/4885RAB9A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.